Key terms
About BNOX
Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. Its lead product candidate is BNC210. The company was founded in 1996 and is headquartered in Eastwood, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BNOX news
Mar 27
12:45pm ET
Buy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study Results
Mar 21
12:05pm ET
Bionomics’s BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Mar 21
6:11am ET
Bionomics’ BNC210 shows significant improvement in PTSD
Jan 22
2:47pm ET
Bionomics: A Strong Buy on Clinical and Regulatory Milestones
Jan 22
6:09am ET
Bionomics provides update on BNC210 development
No recent press releases are available for BNOX
BNOX Financials
Key terms
Ad Feedback
BNOX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BNOX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
